z-logo
open-access-imgOpen Access
Sunitinib-associated hyperammonemic encephalopathy successfully managed with higher intensity conventional hemodialysis
Author(s) -
Sabrina Haroon,
Stephanie Q Ko,
Alvin Wong,
Poh-Seng Tan,
Evan Lee,
Titus Lau
Publication year - 2021
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000024313
Subject(s) - medicine , hemodialysis , sunitinib , encephalopathy , pediatrics , renal cell carcinoma
Rationale: Hyperammonemia encephalopathy is a rare but severe complication that has been reported in association with the use of sunitinib, a tyrosine kinase inhibitor. We report here a unique case of a patient with end stage renal disease that was initiated on sunitinib for metastatic renal cell carcinoma. Patient concerns: A 65-year-old man with end stage renal disease on maintenance conventional hemodialysis and had concomitant stable Child-Pugh class B liver cirrhosis consequent of hepatitis C infection was started on sunitinib for metastatic renal cell carcinoma. He developed confusion few weeks after starting therapy with no other indication of worsening liver dysfunction otherwise. Diagnosis: He was later diagnosed with hyperammonemia encephalopathy. Interventions: His treatment was discontinued and reinitiated at a lower dose after recovery and titrated according to tolerance. As ammonia is a very low molecular weight molecule and is cleared well with diffusive clearance, we intensified his dialysis regimen by increasing intensity for each session and frequency per week. Outcomes: With this change in dialysis regimen, patient was able to continue treatment with sunitinib. Lessons: Clinicians prescribing sunitinib should be vigilant to monitor for this complication in patients receiving sunitinib, apart from the more usual presentation of hepatotoxicity. We found that a more intensive hemodialysis regimen consisting of 4× a week conventional high-flux hemodialysis (HD) can permit the continuation of treatment with sunitinib in an end stage renal disease (ESRD) patient with Child-Pugh class B liver cirrhosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here